novo nordisk eli lilly

News

Novo missed its sales estimates on weight-loss drug Wegovy

Why Novo missed its sales estimates on weight-loss drug Wegovy: CEO

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Euronews on MSN · 13h

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Reuters · 8h

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

Novo Nordisk Stock Jumps

The Motley Fool on MSN · 5d

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

Barron's on MSN · 8h

Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly bigger than what we had anticipated,” Novo Chief Fi

AOL · 11h

Novo Nordisk beats on Q1 earnings, cuts 2025 outlook

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs,

The Economist3h

Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

7hon MSN

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...

6don MSN

Eli Lilly CEO waives off CVS, Novo Nordisk deal: 'It feels a little like last decade'

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

BioSpace8h

Novo Vows Smoother Market Waters for Wegovy—But Analysts Are Skeptical

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

1hon MSN

Ozempic maker Novo Nordisk set for slimmer sales amid surge in copycat weight-loss drugs

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

STAT8d

Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

13h

Novo Nordisk CFO on Wegovy, Tariffs, US Compounding

Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in ...

Fierce Pharma6d

In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results